Tags

Type your tag names separated by a space and hit enter

Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk.
Nutr Metab Cardiovasc Dis 2013; 23(11):1101-6NM

Abstract

BACKGROUND AND AIMS

The ESC/ESH guidelines for arterial hypertension recommend using statins for patients with high cardiovascular (CV) risk for both secondary and primary prevention. A recent meta-analysis, combining previous studies on statins, concluded that they are associated with a 9% increased risk of incident type 2 diabetes mellitus (DM). There is no information on whether statins increase incidence of DM in primary prevention.

METHOD AND RESULTS

We evaluated risk of incident DM in relation to statin prescription in 4750 hypertensive, non-diabetic outpatients (age 58.57 ± 9.0 yrs, 42.3% women), from the CampaniaSalute Network, without chronic kidney disease more than grade 3, free of prevalent CV disease and with at least 12 months of follow-up. DM was defined according to ADA criteria. At the end of follow-up period (55.78 ± 42.5 months), 676 patients (14%) were on statins. These patients were older (62.54 ± 7.3 vs 57.91 ± 9.1 yrs; p < 0.0001), more often female (49% vs 41.2%; p = 0.0001), with higher initial total cholesterol (217.93 ± 44.3 vs 205.29 ± 36.6 mg/dl), non-HDL cholesterol (167.16 ± 44.5 vs 155.18 ± 36.7 mg/dl) and triglycerides (150.69 ± 85.2 vs 130.98 ± 72.0 mg/dl; all p < 0.0001) than patients no taking statins, without other differences in clinical and laboratory characteristics. At the end of follow-up, prevalence of DM was 18.1% among patients on statins and 7.2% among those without lipid-lowering therapy (p < 0.0001). However, incident DM was 10.2% in patients on statins and 8.7% in those free of statin therapy (NS).

CONCLUSION

In real-life outpatient environment, statin prescription for primary prevention is not associated with increased risk of incident DM.

Authors+Show Affiliations

Department of Translational Medical Sciences, Federico II University, Naples, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23419735

Citation

Izzo, R, et al. "Primary Prevention With Statins and Incident Diabetes in Hypertensive Patients at High Cardiovascular Risk." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 23, no. 11, 2013, pp. 1101-6.
Izzo R, de Simone G, Trimarco V, et al. Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk. Nutr Metab Cardiovasc Dis. 2013;23(11):1101-6.
Izzo, R., de Simone, G., Trimarco, V., Giudice, R., De Marco, M., Di Renzo, G., ... Trimarco, B. (2013). Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 23(11), pp. 1101-6. doi:10.1016/j.numecd.2012.11.002.
Izzo R, et al. Primary Prevention With Statins and Incident Diabetes in Hypertensive Patients at High Cardiovascular Risk. Nutr Metab Cardiovasc Dis. 2013;23(11):1101-6. PubMed PMID: 23419735.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk. AU - Izzo,R, AU - de Simone,G, AU - Trimarco,V, AU - Giudice,R, AU - De Marco,M, AU - Di Renzo,G, AU - De Luca,N, AU - Trimarco,B, Y1 - 2013/02/15/ PY - 2012/06/04/received PY - 2012/10/25/revised PY - 2012/11/01/accepted PY - 2013/2/20/entrez PY - 2013/2/20/pubmed PY - 2014/7/16/medline KW - CV risk KW - Diabetes KW - Statins SP - 1101 EP - 6 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 23 IS - 11 N2 - BACKGROUND AND AIMS: The ESC/ESH guidelines for arterial hypertension recommend using statins for patients with high cardiovascular (CV) risk for both secondary and primary prevention. A recent meta-analysis, combining previous studies on statins, concluded that they are associated with a 9% increased risk of incident type 2 diabetes mellitus (DM). There is no information on whether statins increase incidence of DM in primary prevention. METHOD AND RESULTS: We evaluated risk of incident DM in relation to statin prescription in 4750 hypertensive, non-diabetic outpatients (age 58.57 ± 9.0 yrs, 42.3% women), from the CampaniaSalute Network, without chronic kidney disease more than grade 3, free of prevalent CV disease and with at least 12 months of follow-up. DM was defined according to ADA criteria. At the end of follow-up period (55.78 ± 42.5 months), 676 patients (14%) were on statins. These patients were older (62.54 ± 7.3 vs 57.91 ± 9.1 yrs; p < 0.0001), more often female (49% vs 41.2%; p = 0.0001), with higher initial total cholesterol (217.93 ± 44.3 vs 205.29 ± 36.6 mg/dl), non-HDL cholesterol (167.16 ± 44.5 vs 155.18 ± 36.7 mg/dl) and triglycerides (150.69 ± 85.2 vs 130.98 ± 72.0 mg/dl; all p < 0.0001) than patients no taking statins, without other differences in clinical and laboratory characteristics. At the end of follow-up, prevalence of DM was 18.1% among patients on statins and 7.2% among those without lipid-lowering therapy (p < 0.0001). However, incident DM was 10.2% in patients on statins and 8.7% in those free of statin therapy (NS). CONCLUSION: In real-life outpatient environment, statin prescription for primary prevention is not associated with increased risk of incident DM. SN - 1590-3729 UR - https://www.unboundmedicine.com/medline/citation/23419735/Primary_prevention_with_statins_and_incident_diabetes_in_hypertensive_patients_at_high_cardiovascular_risk_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(12)00258-X DB - PRIME DP - Unbound Medicine ER -